Gabapentin Solution
Product Images NDC 81033-123

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 81033-123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kesin Pharma Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Oral Solution 16 Oz Bottle Label (Gabapentin Os Bottle 250mg)

Label for Gabapentin Oral Solution 250 mg/5 mL, a human prescription drug in oral solution form. The label indicates a 16 fl. oz (470 mL) bottle, distributed by Kesin Pharma Corporation. It highlights that each 5 mL contains 250 mg of gabapentin, includes storage instructions to refrigerate at 2°C to 8°C, and notes the product is for institutional use only.*

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Formula (Gabapentin Oral Solution 1)

An equation diagram illustrating the calculation of creatinine clearance (CLCr). The formula incorporates age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Structure (Gabapentin Oral Solution 2)

Chemical structure of Gabapentin, showing a cyclohexane ring bonded to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Diagram1 (Gabapentin Oral Solution 3)

A line graph depicting mean pain scores measured over an eight-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores, with Gabapentin showing a decline in pain scores over time compared to relatively stable scores for placebo.*

FDA Label Image

Diagram2 (Gabapentin Oral Solution 4)

A line graph showing mean pain scores over time during a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo with Gabapentin at 1800 mg/day and 2400 mg/day dosages across 7 weeks, with pain scores decreasing over time for Gabapentin groups compared to placebo.*

FDA Label Image

Diagram3 (Gabapentin Oral Solution 5)

A bar chart showing results from two studies labeled Study 1 and Study 2. The y-axis displays percentages from 0% to 100%. Study 1 compares placebo (PBO) at 12% with Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14% with Gabapentin 1800 mg at 32% and Gabapentin 2400 mg at 34%. Statistical significance indicators are noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Diagram4 (Gabapentin Oral Solution 6)

A scatter plot showing percentage difference on the y-axis versus daily dose in milligrams on the x-axis. The graph includes data points from three studies labeled as Study a, Study b, and Study c, distinguished by different colored squares. Data points appear at daily doses ranging from 600 mg to 1800 mg, with percentage differences from about 7% to 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.